secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001558370-23-008389
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics appoints Gabriela Gruia, M.D. to board; grants 12,500-share option
--------------------------------------------------------------------------------

- Board expanded from 8 to 9 directors; Dr. Gruia appointed as Class II director effective May 5, 2023.
- Option to purchase 12,500 shares at $3.86 (closing price on grant date) fully vesting in one year.
- Dr. Gruia brings 25+ years in oncology drug development; former SVP at Novartis Oncology leading 12 NME approvals.
- No familial or transaction relationships requiring disclosure; serves until 2024 annual meeting or resignation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023008389/0001558370-23-008389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023008389/apre-20230505x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer